Search results for "Antibodies."

showing 10 items of 1857 documents

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Migraine and cluster headache – the common link

2018

Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…

medicine.medical_specialtyNeurologyCluster headacheImplantable Neurostimulators/statistics & numerical dataPain medicineCalcitonin Gene-Related PeptideDeep Brain StimulationMigraine DisordersNitroglycerin/adverse effectsHypothalamuslcsh:MedicineTriptansReviewCalcitonin gene-related peptideBioinformatics03 medical and health sciencesNitroglycerin0302 clinical medicinemedicineHumans030212 general & internal medicineTryptamines/pharmacologyMigraineTrigeminovascular systembusiness.industryNeuromodulationCluster Headache/bloodCluster headacheAnti-CGRP (receptor) monoclonal antibodies – mAbsMigraine Disorders/bloodTrigeminovascular systemlcsh:RGeneral MedicineCalcitonin gene-related peptide (CGRP)medicine.diseaseDeep Brain Stimulation/statistics & numerical dataNeuromodulation (medicine)Tryptamines3. Good healthCalcitonin Gene-Related Peptide/antagonists & inhibitorsAnesthesiology and Pain MedicineImplantable NeurostimulatorsMigraineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugThe Journal of Headache and Pain
researchProduct

Long-Term Evaluation of a Rat Model of Chronic Cholangitis Resembling Human Primary Sclerosing Cholangitis

2003

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder with a presumed autoimmune aetiopathogenesis. We have recently described a novel organ-specific rat model of fibrosing cholangitis induced by intrabiliary administration of the hapten-reagent 2,4,6-trinitrobenzenesulfonic acid (TNBS) with similarities to human PSC. In the present report, we have evaluated the long-term outcome of TNBS-induced cholangitis in this model. Mild stenosis of the common bile duct of female Lewis rats (n = 18) was achieved by subtotal ligation and cholangitis induced by TNBS injection (50 mg/kg) into the dilated bile duct after a second laparotomy. After 8 and 12 months, we found no evidence of …

medicine.medical_specialtyPathologyNecrosisCholangitis SclerosingImmunologyInflammationdigestive systemGastroenterologyAntibodies Antineutrophil CytoplasmicPrimary sclerosing cholangitisCholangiographyInternal medicinemedicineAnimalsHumansChronic CholangitisAnti-neutrophil cytoplasmic antibodymedicine.diagnostic_testCommon bile ductbusiness.industryAlanine TransaminaseGeneral Medicinemedicine.diseaseRatsDisease Models AnimalC-Reactive Proteinmedicine.anatomical_structureLiverTrinitrobenzenesulfonic AcidRats Inbred LewChronic DiseaseDisease ProgressionFemalemedicine.symptomLigationbusinessScandinavian Journal of Immunology
researchProduct

Interrelation of peptidergic innervation with mast cells and ED1-positive cells in rat thymus

1991

The peptidergic innervation of rat thymus has been investigated by immunohistochemical methods, focusing on the spatial interrelationship of peptidergic nerve fibers with mast cells and macrophages in the rat. An antiserum directed against the protein gene product 9.5 (PGP 9.5) regarded as a pan-neuronal marker revealed a rich innervation, especially in the subcapsular cortex, in interlobular septa, and of the vasculature in the cortex and the corticomedullary boundary. A minor proportion of PGP 9.5-immunoreactive (ir) fibers supplied the thymic parenchyma. The main component of peptidergic innervation consisted of fibers costaining for tachykinins (TKs) and calcitonin gene-related peptide …

medicine.medical_specialtyPathologyNeuroimmunomodulationImmunologyVasoactive intestinal peptideConnective tissueNerve fiberThymus GlandBiologyCalcitonin gene-related peptideBehavioral NeuroscienceCatecholaminesNerve FibersInternal medicineCortex (anatomy)medicineAnimalsMast CellsGalaninEndocrine and Autonomic SystemsMacrophagesNeuropeptidesAntibodies MonoclonalCell DifferentiationRats Inbred StrainsMast cellRatsReceptors NeurotransmitterEndocrinologymedicine.anatomical_structurePeripheral nervous systemUbiquitin ThiolesteraseBiomarkersBrain, Behavior, and Immunity
researchProduct

Inhibitors to factor VII in congenital factor VII deficiency.

2014

medicine.medical_specialtyPediatricsFactor VIIbusiness.industryInhibitorsFactor VII DeficiencyMEDLINErVIIaHematologyGeneral MedicineFactor VIIInhibitors Factor VII deficiencyGastroenterologyAntibodieschemistry.chemical_compoundchemistryInternal medicinerVIIa; FVII deficiency; InhibitorsmedicineHumansFVII deficiencyFactor VII deficiencybusinessGenetics (clinical)
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

Search for autoantibodies to the human bradykinin B2 receptor.

1997

medicine.medical_specialtyReceptor Bradykinin B2Blotting WesternMolecular Sequence DataEnzyme-Linked Immunosorbent AssayAntigen-Antibody ComplexCross ReactionsChromatography AffinityCohort StudiesHypertension MalignantAdjuvants ImmunologicInternal medicineMedicineAnimalsHumansAmino Acid SequenceBradykinin receptorAntigensAutoantibodiesPharmacologyBinding Sitesbusiness.industryReceptors BradykininAutoantibodyPrecipitin TestsRecombinant ProteinsEndocrinologyImmunoglobulin GHemocyaninsFemaleRabbitsbusinessPeptidesBradykinin B2 ReceptorBaculoviridaeImmunopharmacology
researchProduct

The new criteria for classification of rheumatoid arthritis: what we need to know for clinical practice.

2011

The new criteria for classification of Rheumatoid Arthritis have been recently released. They incorporate the anti-Citrullinated Protein antibody testing and the other classic criteria in a score system (the diagnosis of definite rheumatoid arthritis is made by a total score ≥6). These criteria try to meet the pressing needs to gain sensitivity in early disease. Symptoms, elevated acute-phase response, serologic abnormality, joint involvement were all considered for scoring after confirming the presence of synovitis in at least 1 joint in the absence of an alternative diagnosis that better explains the synovitis. However, no sensitivity and specificity has been showed. Moreover, Area Under …

medicine.medical_specialtySettore MED/09 - Medicina InternaArthritisDiseasePeptides CyclicSensitivity and SpecificityArthritis RheumatoidRheumatologyInternal medicineSynovitisInternal MedicineMedicineHumansIntensive care medicineAutoantibodiesReceiver operating characteristicbusiness.industryAutoantibodymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheRheumatoid arthritis Classification criteria Anti-citrullinated peptide autoantibodies Bayesian reasoning Likelihood ratio Sensitivity and specificityRheumatologySettore MED/16 - ReumatologiaRheumatoid arthritisPhysical therapyAbnormalitybusinessBiomarkersEuropean journal of internal medicine
researchProduct

The production of the oral mucosa of antiendomysial and anti-tissue-transglutaminase antibodies in patients with celiac disease: a review.

2010

Celiac disease (CD) is a lifelong, T cell—mediated enteropathy, triggered by the ingestion of gluten and related prolamins in genetically susceptible subjects, resulting in minor intestinal mucosal injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis, and subsequent nutrient malabsorption. Although serological tests for antiendomysial (EMA) and anti—tissue transglutaminase (anti-tTG) autoantibodies are used to screen and follow up on patients with CD, diagnostic confirmation is still based on the histological examination of the small intestinal mucosa. Although the small intestinal mucosa is the main site of the gut involved in CD, other mucosal surface…

medicine.medical_specialtySettore MED/09 - Medicina InternaMalabsorptionGlutensTissue transglutaminaseBiopsyantiendomysial antibodieslcsh:Medicineoral biopsyReview Articlelcsh:TechnologyGastroenterologySensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie Odontostomatologicheanti–tissue transglutaminase antibodiesInternal medicineBiopsymedicineHumansEnteropathyOral mucosalcsh:ScienceGeneral Environmental ScienceAutoantibodiesSettore MED/12 - GastroenterologiaGastrointestinal tractTransglutaminasesbiologymedicine.diagnostic_testoral mucosalcsh:Tbusiness.industrylcsh:RMouth MucosaMuscle SmoothGeneral Medicinemedicine.diseaseCeliac Diseasemedicine.anatomical_structureceliac disease oral mucosa anti–tissue transglutaminase antibodies antiendomysial antibodies oral biopsy.Immunologybiology.proteinIntraepithelial lymphocytelcsh:QGliadinbusinessTheScientificWorldJournal
researchProduct